Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nedocromil→

Nedocromil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
69049-73-6
Molecular formula
C19H17NO7
Molecular weight
371.3 g/mol
Drug class
Mast-cell stabiliseranti-allergic cromone derivative
Mechanism of action
Inhibits activation and mediator release from mast cells and other inflammatory cells. The precise molecular mechanism is not fully established; nedocromil is used prophylactically rather than as an acute bronchodilator.
Indications / reported uses
  • Prevention and treatment of allergic conjunctivitis symptoms with authorised ophthalmic formulations
  • Historically used as prophylactic therapy for asthma with inhaled formulations in countries where available; current availability and product authorisation vary

Sources: NLM MeSH — Nedocromil · PubMed — Nedocromil clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nedocromil Environmental Risk Assessment (ERA) (the Nedocromil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.